Application of STAT1 inhibitor in preparation of B-cell lymphoma radiosensitization drug and B-cell lymphoma radiosensitization drug
The invention discloses application of an STAT1 inhibitor in preparation of a B-cell lymphoma radiosensitization medicine and the medicine, and relates to the field of biological medicine. The STAT1 inhibitor is applied to preparation of a ferroptosis inducer or preparation of a B-cell lymphoma radiotherapy sensitizing drug, the STAT1 inhibitor is fludarabine, and it is found that the fludarabine combined radiotherapy means for treatment of B-cell lymphoma has a remarkable effect compared with a single treatment scheme. The ferroptosis inhibitor Liproxstatin-1 weakens the inhibition of fludarabine, radiotherapy and fludarabine combined radiotherapy on the growth of Raji cell xenotransplantation tumors, proves that at least part of fludarabine promotes the death of B cell lymphoma induced by radiotherapy through a ferroptosis pathway, and indicates that fludarabine enhances the ferroptosis effect induced by radiotherapy. The result shows that fludarabine has a radiosensitization effect on B-cell lymphoma..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 13. Juni Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LIU SIHONG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-06-13, Last update posted on www.tib.eu: 2023-09-26, Last updated: 2023-09-29 |
|---|
| Patentnummer: |
CN116251188 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001863177 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001863177 | ||
| 003 | DE-627 | ||
| 005 | 20240327213758.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001863177 | ||
| 035 | |a (EPA)CN116251188 | ||
| 035 | |a (EPA)86678656 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LIU SIHONG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of STAT1 inhibitor in preparation of B-cell lymphoma radiosensitization drug and B-cell lymphoma radiosensitization drug |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-06-13, Last update posted on www.tib.eu: 2023-09-26, Last updated: 2023-09-29 | ||
| 520 | |a The invention discloses application of an STAT1 inhibitor in preparation of a B-cell lymphoma radiosensitization medicine and the medicine, and relates to the field of biological medicine. The STAT1 inhibitor is applied to preparation of a ferroptosis inducer or preparation of a B-cell lymphoma radiotherapy sensitizing drug, the STAT1 inhibitor is fludarabine, and it is found that the fludarabine combined radiotherapy means for treatment of B-cell lymphoma has a remarkable effect compared with a single treatment scheme. The ferroptosis inhibitor Liproxstatin-1 weakens the inhibition of fludarabine, radiotherapy and fludarabine combined radiotherapy on the growth of Raji cell xenotransplantation tumors, proves that at least part of fludarabine promotes the death of B cell lymphoma induced by radiotherapy through a ferroptosis pathway, and indicates that fludarabine enhances the ferroptosis effect induced by radiotherapy. The result shows that fludarabine has a radiosensitization effect on B-cell lymphoma. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a WU YONG |4 aut | |
| 700 | 0 | |a LONG QINGQIN |4 aut | |
| 700 | 0 | |a TAO HUIMIN |4 aut | |
| 700 | 0 | |a WANG PEIPEI |4 aut | |
| 700 | 0 | |a LIU YING |4 aut | |
| 700 | 0 | |a WU BIWEN |4 aut | |
| 700 | 0 | |a ZHU QINGHONG |4 aut | |
| 700 | 0 | |a LI JIAJUN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 13. Juni |
| 773 | 1 | 8 | |g year:2023 |g day:13 |g month:06 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/86678656/publication/CN116251188A1?q=CN116251188 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 13 |c 06 | ||